Recombinant CD80 (Galiximab Biosimilar) antibody

Catalog No. ABIN7795110

The Humanized Monoclonal anti-CD80 (Galiximab Biosimilar) antibody has been validated for FACS and in vivo. It is suitable to detect CD80 (Galiximab Biosimilar) in samples from Human.

Quick Overview for Recombinant CD80 (Galiximab Biosimilar) antibody (ABIN7795110)

Target: CD80 (Galiximab Biosimilar)

Antibody Type: Recombinant Antibody

Reactivity: Human

Host: Humanized

Clonality: Monoclonal

Conjugate: This CD80 (Galiximab Biosimilar) antibody is un-conjugated

Application: Flow Cytometry (FACS), In vivo Studies (in vivo)

Grade: Research Grade

Product Details anti-CD80 (Galiximab Biosimilar) Antibody

Expression System: Mammalian cells

Purpose: Galiximab Biosimilar, CD80 Monoclonal Antibody

Characteristics: A humanized IgG1 monoclonal antibody directed against CD80, the natural ligand for the T-cell antigen CD28 which mediates T-cell and B-cell adhesion. Galiximab binds to CD80 expressed on the cell surfaces of follicular lymphomas, resulting in antibody-dependent cell-mediated cytotoxicity (ADCC). CD80 is expressed on activated B-cells and gamma-interferon-stimulated monocytes and is often expressed at low levels on the surfaces of follicular lymphoma cells and other lymphoid malignancies. Galiximab, an IgG(1) anti-CD80 antibody, binds to CD80, a costimulatory molecule involved in T-cell activation. Reduction in lesional, activated T cells induces improvement in psoriatic plaques.

Purification: Protein A or G affinity column

Purity: >95 % by reducing SDS-PAGE

Endotoxin Level: < 1 EU per 1 mg of the protein by the LAL method

Immunogen: Human CD80

Application Details

Application Notes: Optimal working dilution should be determined by the investigator.

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: > 3 mg/mL

Storage: 4 °C,-20 °C

Storage Comment: Short time 2 to 8°C as supplied. Long time -20°C to -70°C as supplied.

Target Details for CD80 (Galiximab Biosimilar)

Target: CD80 (Galiximab Biosimilar)

Alternative Name: Galiximab Biosimilar

Target Type: Biosimilar